Janssen's sales of Darzalex exceed expectations
Johnson & Johnson’s pharmaceutical arm Janssen has sold more of the Danish-developed cancer drug Darzalex in the first quarter of the year than analysts had anticipated.
Sales of the Genmab-developed bone marrow cancer drug, Darzalex, which Johnson & Johnson has licensed, surpassed projections for the first quarter of 2022, as revealed by Johnson & Johnson’s financial report on Tuesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Genmab loses royalties case against Janssen
For subscribers
Genmab value drops by over USD 1.5bn after royalties defeat
For subscribers
.jpg&w=384&q=75)
